Product Description

Before Mailing, register your DNA test kit at 23andMe online otherwise, your saliva sample will NOT be processed. 23andMe Health + Ancestry Service features over 150 personalized genetic insights that can help make it easier for you to take action on your health. Using insights backed by the latest science, see how DNA can affect your chances of developing certain health conditions.* 23andMe's Health + Ancestry Service provides genetic testing that includes: 10+ Health Predisposition* reports including: Type 2 Diabetes (Powered by 23andMe Research), Late-Onset Alzheimer's Disease, Celiac Disease. 45+ Carrier Status* reports including: Cystic Fibrosis, Sickle Cell Anemia, Tay-Sachs Disease; 5+ Wellness reports including: Deep Sleep, Lactose Intolerance, Genetic Weight. 23andMe Health + Ancestry Service includes our Ancestry Service with over 50 personalized DNA ancestry reports: Ancestry Composition, Ancestry Detail Reports, Maternal & Paternal Haplogroups, Neanderthal Ancestry. Opt-in to find and connect with relatives in the 23andMe database who share DNA with you. And opt-in to Family Tree, which is automatically built from your DNA relationships. Plus 30+ Trait reports including: Hair (Color, Curliness, Male Bald Spot), Taste & Smell (Sweet vs. Salty, Bitter), Facial Features (Cheek Dimples, Unibrow, Freckles). OTHER FEATURES: 23andMe’s at-home saliva test kits include tools that allow you to share, compare and discover more with friends and family. Trace DNA through your close family and explore the genetic similarities and differences between you and family members. At-home DNA test kit. Access to Health + Ancestry Service that can help give you a more complete picture of your health with insights from your genetic data. Personalized genetic insights and tools that can help make it easier for you to take action on your health. Includes FDA-authorized reports and full access to our Ancestry Service.

Legal Disclaimer

* The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk.

**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Results for SLCO1B1 and DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetics reports, visit 23andme. com/test-info/pharmacogenetics/

***Check with your FSA/HSA administrator or your tax professional for specific requirements for individual eligibility and reimbursement.

“92% of doctors say genetics is an important part of a patient’s complete health picture.” Based on 2022 surveys, designed by 23andMe, Medscape, and Material Holdings LLC, of approximately 1,000 doctors and approximately 1,500 patients.

Before you can use 23andMe and see your reports, you must agree to 23andMe's Terms of Service (23andme. com/tos) at the time of registration of your 23andMe kit. Your use of 23andMe is further subject to 23andMe's Privacy Statement (23andme. com/about/privacy).